These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 9112451)
1. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Hanks GE; Schultheiss TE; Hanlon AL; Hunt M; Lee WR; Epstein BE; Coia LR Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):543-50. PubMed ID: 9112451 [TBL] [Abstract][Full Text] [Related]
2. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Hanks GE; Hanlon AL; Schultheiss TE; Pinover WH; Movsas B; Epstein BE; Hunt MA Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):501-10. PubMed ID: 9635695 [TBL] [Abstract][Full Text] [Related]
3. Dose response in prostate cancer with 8-12 years' follow-up. Hanks GE; Hanlon AL; Epstein B; Horwitz EM Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818 [TBL] [Abstract][Full Text] [Related]
4. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy. Horwitz EM; Hanlon AL; Pinover WH; Hanks GE Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):519-23. PubMed ID: 9635697 [TBL] [Abstract][Full Text] [Related]
5. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML. Hanks GE; Lee WR; Hanlon AL; Hunt M; Kaplan E; Epstein BE; Movsas B; Schultheiss TE Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):861-8. PubMed ID: 8751393 [TBL] [Abstract][Full Text] [Related]
6. Postradiotherapy PSA nadirs fail to support dose escalation study in patients with pretreatment PSA values < 10 ng/ml. Herold D; Hanks G; Movsas B; Hanlon A Radiat Oncol Investig; 1997; 5(1):15-9. PubMed ID: 9303052 [TBL] [Abstract][Full Text] [Related]
7. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Pollack A; Smith LG; von Eschenbach AC Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469 [TBL] [Abstract][Full Text] [Related]
8. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Fukunaga-Johnson N; Sandler HM; McLaughlin PW; Strawderman MS; Grijalva KH; Kish KE; Lichter AS Int J Radiat Oncol Biol Phys; 1997 May; 38(2):311-7. PubMed ID: 9226317 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625 [TBL] [Abstract][Full Text] [Related]
10. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788 [TBL] [Abstract][Full Text] [Related]
11. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy. Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119 [TBL] [Abstract][Full Text] [Related]
12. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer. Pinover WH; Hanlon AL; Horwitz EM; Hanks GE Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):649-54. PubMed ID: 10837947 [TBL] [Abstract][Full Text] [Related]
13. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy. Anderson PR; Hanlon AL; Horwitz E; Pinover W; Hanks GE Cancer; 2000 Dec; 89(12):2565-9. PubMed ID: 11135217 [TBL] [Abstract][Full Text] [Related]
14. The 1989 patterns of care study for prostate cancer: five-year outcomes. Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218 [TBL] [Abstract][Full Text] [Related]
15. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group. Lattanzi JP; Hanlon AL; Hanks GE Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):569-73. PubMed ID: 9231681 [TBL] [Abstract][Full Text] [Related]
16. Hazards of dose escalation in prostate cancer radiotherapy. Kuban D; Pollack A; Huang E; Levy L; Dong L; Starkschall G; Rosen I Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1260-8. PubMed ID: 14630260 [TBL] [Abstract][Full Text] [Related]
17. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Bonin SR; Hanlon AL; Lee WR; Movsas B; al-Saleem TI; Hanks GE Cancer; 1997 Jan; 79(1):75-80. PubMed ID: 8988729 [TBL] [Abstract][Full Text] [Related]
18. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961 [TBL] [Abstract][Full Text] [Related]
19. [Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma]. Geinitz H; Zimmermann F; von Wedel E; Thamm R; Busch R; Feldmann HJ; Molls M Strahlenther Onkol; 2002 Jul; 178(7):369-77. PubMed ID: 12163991 [TBL] [Abstract][Full Text] [Related]